Cigna Corporation

(New York Stock Exchange)
Back to all articles
Bullish +65

CVS vs Cigna: Which Healthcare Giant Belongs in Your Retirement Portfolio?

AI-generated analysis

πŸ“Š Cigna trades at a lower valuation multiple of approximately 9.4x trailing adjusted earnings compared to CVS's 11.3x.

πŸ“ˆ Cigna reported strong financial performance with net income growing 73.47% year-over-year in FY2025 to $5.957 billion.

πŸ“‰ CVS experienced a significant decline in profitability, with net income falling 62.55% due to a $5.7 billion goodwill impairment and litigation charges.

πŸ† Cigna achieved consistent execution by beating adjusted EPS estimates in all four quarters of 2025.

πŸ’Š Cigna's specialty care engine, Evernorth Health Services, posted 17% revenue growth in Q4 2025 with pharmacy customers expanding to 123.6 million.

πŸ”„ Cigna aggressively returned capital by repurchasing 11.9 million shares for approximately $3.6 billion in 2025.

πŸ’° CVS offers a higher dividend yield approaching 3.5% with an annualized payout of $2.66, appealing to income-focused investors.

πŸ“‰ CVS operating income fell 45.28% year-over-year despite growth in same-store prescription volume and pharmacy revenue.

πŸ“‰ CVS reduced its 2026 operating cash flow guidance from $10 billion to at least $9.0 billion.

πŸ“ˆ Cigna has delivered superior long-term performance, compounding returns of 101.36% over the past decade versus CVS's 1.84%.

Bullish Signals
  • Cigna demonstrated exceptional earnings quality with net income surging 73.47% year-over-year in FY2025 to reach $5.957 billion.
  • The company maintained a perfect track record of beating adjusted EPS estimates in all four quarters of 2025, showing consistent execution.
  • Cigna's specialty care engine, Evernorth Health Services, achieved 17% revenue growth in Q4 2025 while expanding its pharmacy customer base to 123.6 million.
  • Management aggressively returned capital to shareholders by repurchasing 11.9 million shares for approximately $3.6 billion during 2025.
  • Cigna improved its SG&A ratio to 5.0% from 5.9% year-over-year, indicating better operational efficiency and cost control.
  • The stock has delivered robust long-term performance with a total return of 101.36% over the past decade compared to CVS's minimal growth.
Risk Factors
  • The company trades at a forward multiple of roughly 9.3x against CVS's 10.7x, which may limit upside if the market re-rates healthcare valuations higher.
Full Analysis
This article compares CVS Health (NYSE: CVS) and Cigna Group (NYSE: CI) as potential holdings for retirement portfolios, highlighting that both are currently trading at historically low valuations. Cigna is noted for being cheaper on key metrics, trading at approximately 9.4x trailing adjusted earnings compared to CVS's 11.3x. The analysis emphasizes Cigna's superior earnings quality, citing a 73.47% year-over-year net income growth in FY2025 to $5.957 billion, whereas CVS saw its net income fall 62.55% due to significant goodwill impairment and litigation charges. Cigna demonstrated consistent execution by beating adjusted EPS estimates in all four quarters of 2025, with its specialty care engine, Evernorth Health Services, posting 17% revenue growth in Q4. The company also aggressively returned capital through share repurchases, buying back 11.9 million shares for roughly $3.6 billion in 2025. In contrast, CVS showed mixed results with growing pharmacy revenue but a sharp 45.28% decline in operating income and a reduction of its 2026 operating cash flow guidance from $10 billion to at least $9.0 billion. The piece concludes that while CVS offers a higher dividend yield approaching 3.5% suitable for income-focused retirees, Cigna is positioned as the stronger long-term wealth builder over a 10-to-15-year horizon. Over the past decade, Cigna has compounded returns at 101.36%, significantly outperforming CVS's 1.84%. The author suggests that while CVS requires stabilization in its Health Care Benefits segment, Cigna continues to demonstrate consistent operational discipline and capital efficiency.